When Does Drug Resistant TB Strike HIV/TB Patients?—A South India Experience
- 1 State TB Office, Revised National TB Control Programme, Bangalore, India
- 2 ESIC Medical College and PGIMSR, Bangalore, India
- 3 The Union, South East Asia Office, New Delhi, India
- 4 State TB Office, Revised National TB Control Programme, Bangalore, India
- 5 National AIDS Control Organization, New Delhi, India
Abstract
Background: India is a high TB (tuberculosis) burden country. The advent of HIV (Human immunodeficiency virus) and DR-TB (drug resistant TB) has worsened the ongoing TB control efforts. A study was conducted to (a) to determine the duration for developing drug resistant TB after diagnosis of HIV (b) to ascertain the patients status after one year of DR-TB treatment in Karnataka, India. M ethods: It is a retrospective cross-sectional study involving review of records and reports at ART (Anti-retroviral treatment) centres and DR-TB centres in Karnataka during the period 2013-2014. Results: The median time from being known as HIV positive to being diagnosed as DR-TB was 1168 days (IQR: 571 - 1955). At the end of 14 months, nearly 39% of patients had died and 49% of patients were on treatment. Conclusion: The National Health programmes should prioritize monitoring of the HIV/TB patients and develop appropriate novel strategies for community involvement.
- National AIDS Control Organization and Central TB Division, Government of India. National Framework for Joint HIV/TB Collaborative Activities. October 2009.
- Central TB Division, Ministry of Health and Family Welfare, Government of India. Annual status report, TB India 2014.
- Ramachandran, R., Nalini, S., Chandrasekar, V., Dave, P.V., Sanghvi, A.S., Wares, F., et al. (2009) Surveillance of Drug-Resistant Tuberculosis in the State of Gujarat, India. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease [Internet], 13, 1154-1160. http://www.ncbi.nlm.nih.gov/pubmed/19723407
- World Health Organization (2011) Guidelines for the Programmatic Management of Drug Resistant TB.
- Llaro, K., Bonilla, C., Sebastian, J., Bayona, J., Lygizos, M., Anger, H., et al. (2012) HIV-Positive Patients Treated for Multidrug-Resistant Tuberculosis: Clinical outcomes in the HAART Era. The International Journal of Tuberculosis and Lung Disease, 16, 348-354.
- Gandhi, N.R., Shah, N.S., Andrews, J.R., Vella, V., Moll, A.P., Scott, M., et al. (2010) HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality. American Journal of Respiratory and Critical Care Medicine [Internet], 181, 80-86. http://www.ncbi.nlm.nih.gov/pubmed/19833824
- Isaakidis, P., Paryani, R., Khan, S., Mansoor, H. and Manglani, M. (2013) Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India. PLoS One, 8, Article ID: e68869.
- Isaakidis, P., Cox, H.S., Varghese, B., Montaldo, C., Da Silva, E., Mansoor, H., et al. (2011) Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. PloS One [Internet], 6, Article ID: e28066. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3228724&tool=pmcentrez& rendertype=abstract
- Li, J., Munsiff, S.S., Driver, C.R. and Sackoff, J. (2005) Relapse and Acquired Rifampin Resistance in HIV-Infected Patients with Tuberculosis Treated with Rifampin- or Rifabutin-Based Regimens in New York City, 1997-2000. Clinical Infectious Diseases, 41, 83-91.